Introduction
============

Meta-analysis of 23 randomized controlled trials (RCTs) with durations of 3--26 weeks has found that soy protein ingested with isoflavones intact significantly decreased serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C); subgroup analyses demonstrated that studies employing intakes of \>80 mg isoflavones/day showed better effects, and that the lowering effects were most marked within 3--12 weeks ([@b35-tcrm-4-1097]). Our previous meta-analysis of 11 RCTs found that ingestion of soy protein with a high isoflavone content reduced serum LDL-C to a greater degree than ingestion of the same amount of soy protein with a low isoflavone content for 1--3 months ([@b28-tcrm-4-1097]). These two meta-analyses suggested that soy isoflavones would have synergistic or additive effects on cholesterol lowering when provided concurrently with soy protein for 1--3 months. However, the effects of extracted soy isoflavones alone (not ingested concurrently with soy protein) are unclear.

Meta-analysis of RCTs employing isoflavones in tablet form demonstrated non-significant effects on TC and LDL-C; however, only 5 of the 10 studies evaluated soy-derived isoflavones ([@b33-tcrm-4-1097]). So far, only one meta-analysis of RCTs has evaluated the effects on lipid of soy isoflavones without soy protein. This included 9 trials lasting 4--26 weeks, and revealed a nonsignificant effect of extracted soy isoflavones on LDL-C, although there was a high degree of heterogeneity in mean net changes across the studies ([@b2-tcrm-4-1097]).

We have identified several other recently published RCTs of soy-derived isoflavones, and the present meta-analysis was performed to clarify the effects of extracted soy isoflavones ingested alone for 1--3 months on TC and LDL-C, independent of any effect of soy protein on the same parameters.

Subjects and methods
====================

Study identification and selection
----------------------------------

MEDLINE (1966--2007), EMBASE (1966--2007), CENTRAL (1966--2007), ICHUSHI (1983--2008), and CNKI (1979--2007) were searched for randomized placebo-controlled trials published in English, Japanese, or Chinese describing the effects of ingesting extracted soy isoflavones for 1--3 months in adult humans. Reference lists of relevant systematic reviews ([@b2-tcrm-4-1097]; [@b3-tcrm-4-1097]; [@b23-tcrm-4-1097]), and meta-analyses ([@b33-tcrm-4-1097]; [@b35-tcrm-4-1097]) were hand-searched.

After excluding two RCTs ([@b29-tcrm-4-1097]; [@b1-tcrm-4-1097]) that were subset analyses of an original trial ([@b21-tcrm-4-1097]) and two ([@b17-tcrm-4-1097]; [@b22-tcrm-4-1097]) in which actual endpoint TC and LDL-C values were not clear, 12 RCTs ([@b20-tcrm-4-1097]; [@b26-tcrm-4-1097]; [@b9-tcrm-4-1097]; [@b31-tcrm-4-1097], [@b32-tcrm-4-1097], [@b30-tcrm-4-1097]; [@b21-tcrm-4-1097]; [@b34-tcrm-4-1097]; [@b10-tcrm-4-1097]; [@b12-tcrm-4-1097]; [@b4-tcrm-4-1097]; [@b11-tcrm-4-1097]) and 10 RCTs ([@b20-tcrm-4-1097]; [@b26-tcrm-4-1097]; [@b31-tcrm-4-1097], [@b30-tcrm-4-1097]; [@b21-tcrm-4-1097]; [@b34-tcrm-4-1097]; [@b10-tcrm-4-1097]; [@b12-tcrm-4-1097]; [@b4-tcrm-4-1097]; [@b11-tcrm-4-1097]) that had respectively evaluated the effects of ingesting extracted soy isoflavones alone on TC and LDL-C in adult humans for 1--3 months, and had reported actual endpoint values for each of the comparison groups, were included in the meta-analysis. Two trials ([@b34-tcrm-4-1097]; [@b10-tcrm-4-1097]) and one trial ([@b10-tcrm-4-1097]) were subsequently withdrawn, leaving 10 and 9 RCTs with usable information that were finally selected for meta-analysis of TC and LDL-C, respectively (see [Figure 1](#f1-tcrm-4-1097){ref-type="fig"}). Two reviewers independently reviewed and evaluated the studies, and consensus was reached by discussion when there were disagreements.

Data extraction
---------------

Data on study design and duration, subjects, total soy isoflavones, baseline TC and LDL-C for the isoflavone group, the numbers of participants (N) in each of the comparison groups, and the means and SDs of the endpoint TC and LDL-C values were independently extracted for meta-analysis by two reviewers with double-checking. Normally, serum cholesterol and TG concentrations are about 3% higher than corresponding plasma concentrations ([@b18-tcrm-4-1097]), but because we were interested in mean differences in each study, we analyzed plasma and serum concentrations without correction for this difference; all results are reported as blood concentrations here.

Assessment of study quality
---------------------------

Sensitivity analyses on the basis of methodological quality demonstrated that poor-quality studies indicated a positive effect of treatment, whereas no benefit was observed in high-quality studies ([@b14-tcrm-4-1097]). We used the Jadad scale ([@b13-tcrm-4-1097]) to assess the quality of RCTs included in the meta-analysis. The Jadad scale assesses randomization, blinding, and reporting of withdrawal and dropouts, and assigns studies quality scores ranging from 0 to 5, with a score of \>2 indicating high quality ([@b16-tcrm-4-1097]; [@b27-tcrm-4-1097]). Concealment of treatment allocation in RCTs was assessed as adequate, inadequate, or unclear ([@b24-tcrm-4-1097]).

Meta-analysis
-------------

We performed the meta-analysis to determine the combined effect of extracted soy isoflavones alone on TC and LDL-C using the weighted mean difference method in REVMAN (version 4.2.10; Cochrane Collaboration, Oxford, UK), by inputting the N and the means and SDs of endpoint lipid concentrations for two groups in each comparison. The treatment effect was estimated as the mean difference in endpoint values between comparison groups (ie, the value for subjects ingesting extracted soy isoflavones alone minus that for subjects ingesting a placebo). We did not use mean change from baseline outcomes instead of mean endpoint value outcomes, because mean changes were not available in most of the included studies, and imputed SDs of the changes should not be used for a majority of studies in a meta-analysis ([@b7-tcrm-4-1097]). Although 2 of the 12 RCTs reported both endpoint values and changes ([@b21-tcrm-4-1097]) or percentage changes ([@b11-tcrm-4-1097]) from the baseline, we used endpoint value outcomes to maintain consistency across trials.

We used either a fixed effect model or a random effects model to calculate weighted mean differences (WMD), 95% CIs for each comparison, a combined overall effect with *P*-value, and the *P*-value for testing heterogeneity (*P* \< 0.1 was considered significant). We presented the results based on the random effects model when there was heterogeneity that could not be readily explained ([@b35-tcrm-4-1097]; [@b7-tcrm-4-1097]); otherwise, the results obtained using the fixed effect model were presented.

To explore the possible reasons for differences in results across trials, especially when the test for heterogeneity was significant (*P* \< 0.1 or *I*^2^ \> 25%) ([@b7-tcrm-4-1097]; [@b19-tcrm-4-1097]), we performed subgroup meta-analyses based on variability in the participants' baseline TC and LDL-C, intervention duration, dose of soy isoflavones, study design and study quality ([@b33-tcrm-4-1097]; [@b35-tcrm-4-1097]). Sensitivity analyses were performed on the basis of participants' baseline TC and LDL-C, dose of soy isoflavones, and study quality. We examined potential publication bias by using funnel plots of the SEs of the studies against their corresponding effect sizes.

Results
=======

Study and treatment group characteristics
-----------------------------------------

The characteristics of the 12 RCTs included in the meta-analysis are summarized in [Table 1](#t1-tcrm-4-1097){ref-type="table"}. Six trials used a parallel design, and the remaining trials used a crossover design. Concealment of treatment allocation for all trials was assessed as "unclear" due to insufficient information. All trials focused on menopausal women. Doses of total soy isoflavones were 42--150 mg/day (27--132 mg/day expressed as the aglycone form). One trial ([@b34-tcrm-4-1097]) reported extremely small SDs for endpoint TC values, compared with SDs for other lipids in the trial and SDs reported in remaining trials. Significantly different endpoint TC and LDL-C values between the two comparison groups were reported in two trials ([@b34-tcrm-4-1097]; [@b10-tcrm-4-1097]) and one trial ([@b10-tcrm-4-1097]), respectively, possibly due to their significantly different baseline values; the remaining trials did not reported significantly different TC and LDL-C values at the baseline and endpoint between comparison groups.

In addition, subjects in most of the comparisons had similar diets, with similar amounts of fat (total and saturated), cholesterol, and fiber. Most of the studies were designed to maintain subjects' usual diets and lifestyles. No significant differences in age, body weight, or body mass index were reported between the comparison groups.

Adverse events of extracted soy isoflavones were evaluated according to the evidence report ([@b2-tcrm-4-1097]). Of the 12 RCTs included, one trial ([@b10-tcrm-4-1097]) that used 100 mg soy isoflavones/day reported one case of abdominal bloating and one case of nicturia; one trial ([@b21-tcrm-4-1097]) using 114 mg soy isoflavones/day reported two cases of gastralgia and one recurrence of breast cancer; one trial ([@b26-tcrm-4-1097]) using 80 mg soy isoflavones/day reported one case of paresthesia and one case of brief menstrual period 5 weeks into the treatment (the subject being \>2 years postmenopausal).

Meta-analysis
-------------

Meta-analysis of the 12 RCTs that reported the endpoint TC demonstrated significant heterogeneity (*P* \< 0.00001). Use of the random effects model did not reveal any significant effect of extracted soy isoflavones alone on TC. Excluding two outlying trials ([@b34-tcrm-4-1097]; [@b10-tcrm-4-1097]) showing the poorest overlap (apparently due to the extremely small SDs and significant difference in baseline values) on the forest plot, meta-analysis of 10 RCTs with usable information (see [Figure 1](#f1-tcrm-4-1097){ref-type="fig"}) using the fixed effect model demonstrated nonsignificant heterogeneity and a nonsignificant effect of an average intake of 73 (27--132, as the aglycone form) mg soy isoflavones/day on TC (0.01 mmol/L \[95% CI: --0.12, 0.14\]; *P* = 0.86). Results obtained using the random effects model were identical.

Meta-analysis of the 10 RCTs that reported the endpoint LDL-C demonstrated significant heterogeneity (*P* = 0.003), and use of the random effects model revealed no significant effect of extracted soy isoflavones alone on LDL-C. Excluding one outlying trial ([@b10-tcrm-4-1097]) with the poorest overlap (apparently due to the significant difference in baseline values) on the forest plot, meta-analysis of 9 RCTs with usable information (see [Figure 1](#f1-tcrm-4-1097){ref-type="fig"}) demonstrated nonsignificant heterogeneity and a nonsignificant effect of an average intake of 67 (27--132, as the aglycone form) mg soy isoflavones/day using the fixed effect model (see [Figure 2](#f2-tcrm-4-1097){ref-type="fig"}) on LDL-C (0.03 mmol/L \[95% CI: --0.11, 0.16\]; *P* = 0.71). Results obtained using the random effects model were similar.

Subgroup analyses for the effect on LDL-C found that trials lasting \>2 months resulted in significant heterogeneity and that trials with a parallel design resulted in a significant effect (see [Table 2](#t2-tcrm-4-1097){ref-type="table"}). Subgroup analyses for the effect on TC on the basis of the same variables did not reveal any subgroups with significant results. Sensitivity analyses excluding one trial with LDL-C ≤ 3.36 mmol/L ([@b4-tcrm-4-1097]) or one trial with TC \> 6.21 mmol/L ([@b9-tcrm-4-1097]), trials that evaluated 20--40 (or \> 80) mg soy isoflavone aglycones/day, or trials of poor quality did not significantly influence the results. The funnel plots for the effects on TC and LDL-C did not indicate any obvious publication bias (data not shown).

Discussion
==========

Although two previous meta-analyses have suggested that soy isoflavones have synergistic or additive effects in lowering TC and LDL-C when provided concurrently with soy protein for 1--3 months, especially in hypercholesterolemic (TC \> 6.21 mmol/L or LDL-C \> 4.14 mmol/L) subjects ([@b35-tcrm-4-1097]; [@b28-tcrm-4-1097]), the present meta-analysis found that ingestion of an average of 70 mg extracted soy isoflavones/day (as the aglycone form) alone (not ingested concurrently with soy protein) for 1--3 months did not significantly change TC and LDL-C compared with placebo in normocholesterolemic menopausal women. The inconsistency of the results might be due mainly to the differences in effects between extracted soy isoflavones alone and soy isoflavones provided concurrently with soy protein. Another explanation might be that the two previous meta-analyses included more trials evaluating the effects of soy protein using larger amounts of soy-associated isoflavones in hypercholesterolemic subjects and used different approaches to determine the combined treatment effects. The lack of any beneficial effects of extracted soy isoflavones alone on TC and LDL-C was consistent with a previous meta-analysis that evaluated RCTs of soy isoflavones without soy protein ([@b2-tcrm-4-1097]). However, that study noted a high degree of heterogeneity with mean net changes across the 9 included trials with durations of 4--26 weeks using the inverse variance method and by arbitrarily assuming the correlation coefficient between baseline and endpoint lipid values to be 0.5.

A large cohort study reported that high isoflavone intake from soy foods was associated with a reduced risk of cerebral and myocardial infarction in Japanese women, the risk reduction being pronounced for postmenopausal women ([@b15-tcrm-4-1097]). It is still unclear why intake of isoflavones as a component of intact soy protein or soy foods had beneficial effects on lipid profile, whereas extracted soy isoflavones alone had no such effects. When producing the soy isoflavone extract, alcohol extraction may have removed the active agent, the isoflavones may have been inactivated during the process of purification, or some enabling factor in soy protein may be required for the beneficial effects of soy isoflavones on lipid profiles ([@b5-tcrm-4-1097]). The beneficial effects of soy protein might require synergistic interaction between isoflavones and other soy components ([@b6-tcrm-4-1097]). Isoflavone glycosides are not absorbed intact across the enterocytes of healthy adults, and their bioavailability requires initial hydrolysis by intestinal β-glucosidases for uptake to the peripheral circulation ([@b25-tcrm-4-1097]). Absorption of isoflavones is affected by food matrix and processing in humans ([@b8-tcrm-4-1097]), and differences in bioavailability between soy isoflavones contained in intact soy protein and in various extract supplements (without soy protein) may account for the differences in effects on lipid profiles.

Subgroup and sensitivity analyses based on participants' baseline lipid values, soy isoflavone dose, and study quality revealed no significant influence of extracted soy isoflavones on TC and LDL-C. However, interpretation of the results for any of the variables considered is limited because of the small number of trials available. We did not conduct subgroup analysis to evaluate the effect of isoflavone metabolites (equol and O-DMA) because only one trial had reported that being an equol producer or nonproducer was not a factor influencing the effects of extracted soy isoflavones on lipid profiles ([@b21-tcrm-4-1097]); another trial reported the urinary excretion of equol and O-DMA for equol producers and nonproducers, but did not address the effect on lipids.

In conclusion, our meta-analysis has shown that ingestion of about 70 mg extracted soy isoflavones/day (as the aglycone form) alone (not ingested concurrently with soy protein) for 1--3 months does not decrease blood TC and LDL-C levels in normocholesterolemic menopausal women. Further studies are needed to verify the long-term effects of extracted soy isoflavones alone in other subjects and possible adverse events.
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![The QUOROM statement flow diagram.\
**Notes:** Potentially relevant randomized controlled trials (RCTs) were identified from database PubMed (n = 837), CENTRAL (n = 386), EMBASE (382), ICHUSHI (n = 62) and CNKI (n = 236).\
**Abbreviations:** QUOROM, quality of reports of meta-analyses of randomized controlled trials; RCTs, randomized controlled trials; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol.](tcrm-4-1097f1){#f1-tcrm-4-1097}

![Effect of extracted soy isoflavones (ESI) alone on blood LDL cholesterol.\
**Notes:** Weight assigned by REVMAN software based on N and SD. WMD, Weighted mean difference in endpoint values between the ESI alone (not ingested concurrently with soy protein) and placebo groups; fixed, fixed effect model. Horizontal lines denote the 95% CI. ▪, point estimate (size of the square corresponds to its weight); ♦, combined overall effect of ESI treatment.](tcrm-4-1097f2){#f2-tcrm-4-1097}

###### 

Characteristics of 10 included randomized placebo-controlled trials with usable information

  Study and reference   Design and duration[a](#tfn1-tcrm-4-1097){ref-type="table-fn"}   Subjects[b](#tfn2-tcrm-4-1097){ref-type="table-fn"}   Total soy isoflavones (mg/d)[c](#tfn3-tcrm-4-1097){ref-type="table-fn"}   Jadad scale   Baseline lipids[d](#tfn4-tcrm-4-1097){ref-type="table-fn"}   
  --------------------- ---------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------- ------------- ------------------------------------------------------------ --------------------------------------------------
  [@b4-tcrm-4-1097]     P; R+; DB+; WD (15%); 3 mo                                       60 healthy PoW                                        60 \[37 (De, 41%; Ge, 52%; Gle, 7%)\]                                     5             5.70                                                         3.10
  [@b9-tcrm-4-1097]     P; R; DB; WD (0%); 2 mo                                          36 PoW                                                150 (Ge, 27%; De and Gle, 33%; glycosides, 40%) \[128\]                   3             6.80                                                         NR
  [@b10-tcrm-4-1097]    P; R; DB+; 12 wk                                                 29 healthy PoW                                        \[95 (De, 49%; Ge, 51%)\]                                                 3             5.50[\*](#tfn5-tcrm-4-1097){ref-type="table-fn"}             3.40[\*](#tfn5-tcrm-4-1097){ref-type="table-fn"}
  [@b11-tcrm-4-1097]    CO; R+; DB+; WD (19%); 12 wk                                     32 type 2 diabetes PoW                                \[132 (De, 37%; Ge, 53%; Gle, 10%)\]                                      5             5.40                                                         3.40
  [@b12-tcrm-4-1097]    CO; R; DB+; WD (12%); 8 wk                                       117 healthy PoW                                       \[50 (De, 33%; Ge, 67%)\]                                                 4             6.03                                                         3.88
  [@b20-tcrm-4-1097]    CO; R; SB; WD (9%); 5 wk                                         23 MPW                                                \[80 (De, 42%; Ge, 54%; Gle, 4%)\]                                        2             5.54                                                         3.57
  [@b21-tcrm-4-1097]    CO; R+; DB+; WD (10%); 3 mo                                      62 PoW with a history of breast cancer                \[114 (De, 36%; Ge, 6%; Gle, 58%)\]                                       5             5.88                                                         3.87
  [@b26-tcrm-4-1097]    CO; R; DB+; WD (13%); 8 wk                                       23 healthy PoW                                        \[80 (De and Ge, 100%)\]                                                  4             5.86                                                         3.94
  [@b31-tcrm-4-1097]    P; R; DB; WD (0%); 4 wk                                          23 healthy PW                                         62 \[38 (De, 52%; Ge, 11%; Gle, 37%)\]                                    3             5.85                                                         3.83
  [@b32-tcrm-4-1097]    P; R; WD (4%); 3 mo                                              22 PoW                                                62 \[38 (De, 52%; Ge, 11%; Gle, 37%)\]                                    2             5.79                                                         NR
  [@b30-tcrm-4-1097]    CO; R; DB+; 4 wk                                                 58 CW                                                 42 \[27 (De, 46%; Ge, 13%; Gle, 41%)\]                                    3             5.87                                                         3.62
  [@b34-tcrm-4-1097]    P; R; SB; WD (0%); 3 mo                                          80 healthy PoW                                        \[40 mg/d (Ge, 100%)\]                                                    2             5.81[\*](#tfn5-tcrm-4-1097){ref-type="table-fn"}             3.98

**Notes:**P, Parallel; CO, crossover; R, randomized; R+, randomized by appropriate method; DB, double-blinded; DB+, double-blinded by appropriate method; SB, single-blinded; WD, withdrawals and dropouts described.

Number randomized; PoW, postmenopausal women; MPW, menopausal and perimenopausal women; PW, perimenopausal women; CW, climacteric women.

Values in brackets are expressed as the aglycone form; De, daidzein; Ge, genistein; Gle, glycitein.

Total cholesterol (TC) and LDL cholesterol (LDL-C) concentration (mmol/L) for soy isoflavones treatment group; to convert mg/dL to mmol/L, multiply by 0.02586;

*P* \< 0.05 vs. placebo.

###### 

Combined treatment effect of extracted soy isoflavones alone on LDL cholesterol in subgroup analyses

  Variables                    No. of trials   Sample size (ESI/PLA)   WMD (95% CI) (mmol/L)   *P* for effect   *P* for heterogeneity
  ---------------------------- --------------- ----------------------- ----------------------- ---------------- -----------------------
  Baseline LDL cholesterol                                                                                      
    ≤33.36 mmol/L              1               26/21                   −0.04 (−0.86, 0.06)     0.09             Not available
    \>33.36 mmol/L             8               330/328                 0.07 (−0.08, 0.21)      0.35             0.47
  Study duration                                                                                                
    ≤32 mo                     5               228/226                 0.06 (−0.11, 0.24)      0.49             0.87
    \>32 mo                    4               128/123                 −0.07 (−0.46, 0.31)     0.70             0.04
  Total isoflavone aglycones                                                                                    
    20--40 mg/d                4               116/110                 −0.11 (−0.35, 0.13)     0.35             0.11
    41--80 mg/d                3               158/157                 0.02 (−0.19, 0.23)      0.83             0.91
    \>380 mg/d                 2               82/82                   0.24 (−0.05, 0.54)      0.10             0.43
  Daidzein and genistein                                                                                        
    20--40 mg/d                4               116/110                 −0.11 (−0.35 0.13)      0.35             0.11
    41--80 mg/d                4               214/213                 0.10 (−0.09, 0.28)      0.30             0.52
    \>380 mg/d                 1               26/26                   0.10 (−0.36, 0.56)      0.67             Not available
  Study design                                                                                                  
    Parallel                   3               58/52                   −0.42 (−0.75, 0.08)     0.02             0.97
    Crossover                  6               298/297                 0.11 (−0.04, 0.27)      0.14             0.79
  Study quality                                                                                                 
    High                       7               315/308                 0.06 (−0.10, 0.21)      0.47             0.30
    Poor                       2               41/41                   −0.09 (−0.39, 0.21)     0.57             0.12

**Abbreviations:** WMD, weighted mean difference; ESI, extracted soy isoflavones; PLA, placebo.
